A future approach to treatment of tumours with high expression of MGMT may consist of depletion of tumour MGMT with O6-BG and protection of sensitive bone marrow cells, using genetic modification with O6-BG-resistant MGMT mutants, such as P140 K and G156A. This evidence concerns the gene MGMT and neoplasm.